Zalicus Inc. (ZLCS)
-NasdaqCM | Prev Close: | 1.18 |
|---|
| Open: | N/A |
|---|
| Bid: | 1.10 x 100 |
|---|
| Ask: | 1.22 x 200 |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 4-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.43 - 1.23 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,849,260 |
|---|
| Market Cap: | 156.88M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 27)
- Zalicus’ Z160 Receives Orphan Drug Designation for the Management of Postherpetic NeuralgiaBusiness Wire(Fri, Sep 27)
- Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticalsat Seeking Alpha(Fri, Sep 20)
- ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, Sep 9)
- Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of PainBusiness Wire(Mon, Sep 9)
- Zalicus to Present at the Rodman & Renshaw 15th Annual Global Investment ConferenceBusiness Wire(Tue, Sep 3)
- Zalicus completes patient enrollment in two Z160 phase 2 studiestheflyonthewall.com(Tue, Sep 3)
- ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Sep 3)
- Zalicus Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic PainBusiness Wire(Tue, Sep 3)
- ZALICUS INC. FinancialsEDGAR Online Financials(Sat, Aug 10)
- ZALICUS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Aug 5)
- For Zalicus, Z160 Data In October Could Be Hugeat Seeking Alpha(Thu, Aug 1)
- Zalicus Reports Financial Results for the Second Quarter 2013Business Wire(Thu, Aug 1)
- ZALICUS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, Aug 1)
- Zalicus Publishes Data on Selective Estrogen Receptor Modulators for the Treatment of Infectious DiseaseBusiness Wire(Wed, Jun 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 10.55 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.30 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.08 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of novel treatments for patients suffering from pain. The company develops Z160, a novel oral N-type calcium channel blocker that is under 2 Phase 2a clinical tria...
View More